449 related articles for article (PubMed ID: 33211801)
21. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.
Huang P; Wang Y; Yue M; Ge Z; Xia X; Jeyarajan AJ; Holmes JA; Yu R; Zhu C; Yang S; Lin W; Chung RT
Liver Int; 2021 Oct; 41(10):2341-2357. PubMed ID: 34051040
[TBL] [Abstract][Full Text] [Related]
22. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
23. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
24. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
[TBL] [Abstract][Full Text] [Related]
25. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.
Shafran SD
Clin Infect Dis; 2015 Oct; 61(7):1127-34. PubMed ID: 26060286
[TBL] [Abstract][Full Text] [Related]
26. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
27. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
Abadía M; Montes ML; Ponce D; Froilán C; Romero M; Poza J; Hernández T; Fernández-Martos R; Olveira A;
World J Gastroenterol; 2019 Jun; 25(21):2665-2674. PubMed ID: 31210717
[TBL] [Abstract][Full Text] [Related]
28. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
[TBL] [Abstract][Full Text] [Related]
29. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Mira JA; Neukam K; López-Cortés LF; Rivero-Juárez A; Téllez F; Girón-González JA; de los Santos-Gil I; Ojeda-Burgos G; Merino D; Ríos-Villegas MJ; Collado A; Torres-Cornejo A; Macías J; Rivero A; Pérez-Pérez M; Pineda JA; ;
Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1879-84. PubMed ID: 26115631
[TBL] [Abstract][Full Text] [Related]
31. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs.
Márquez-Coello M; Arizcorreta A; Rodríguez-Pardo M; Illanes-Álvarez F; Márquez D; Cuesta-Sancho S; Girón-González JA
Sci Rep; 2021 May; 11(1):9824. PubMed ID: 33972651
[TBL] [Abstract][Full Text] [Related]
32. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
Sikavi C; Najarian L; Saab S
Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
[TBL] [Abstract][Full Text] [Related]
33. HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests.
Domínguez Domínguez L; Matarranz M; Lagarde M; Bisbal O; Hernando A; Lumbreras C; Rubio R; Pulido F
Rev Esp Enferm Dig; 2019 Aug; 111(8):626-632. PubMed ID: 31240941
[TBL] [Abstract][Full Text] [Related]
34. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
[TBL] [Abstract][Full Text] [Related]
35. RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
Calvaruso V; Celsa C; D'Ambrosio R; Simone F; Petta S; Cacciola I; Enea M; Battaglia S; Pandolfo A; Licata M; Degasperi E; Cabibbo G; Di Marco L; Pennisi G; Borghi M; Di Martino V; Filomia R; Abdel-Hadi Y; Crapanzano L; Raimondo G; Lampertico P; Craxì A; Cammà C; Di Marco V
Am J Gastroenterol; 2022 Nov; 117(11):1816-1824. PubMed ID: 35973181
[TBL] [Abstract][Full Text] [Related]
36. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
37. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.
Lodi S; Klein M; Rauch A; Epstein R; Wittkop L; Logan R; Rentsch CT; Justice AC; Touloumi G; Berenguer J; Jarrin I; Egger M; Puoti M; D'Arminio Monforte A; Gill J; Salmon Ceron D; van Sighem A; Linas B; van der Valk M; Hernán MA;
J Int AIDS Soc; 2022 Dec; 25(12):e26048. PubMed ID: 36562643
[TBL] [Abstract][Full Text] [Related]
38. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
Corma-Gómez A; Macías J; Merino Muñoz D; Téllez F; Granados R; Morano LE; De Los Santos Gil I; Vera-Méndez FJ; Collado A; Palacios R; Pineda JA
J Infect; 2019 Jul; 79(1):30-35. PubMed ID: 31100364
[TBL] [Abstract][Full Text] [Related]
39. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.
Chuaypen N; Jinato T; Avihingsanon A; Chirapongsathorn S; Cheevadhanarak S; Nookaew I; Tanaka Y; Tangkijvanich P
J Infect Dis; 2021 Oct; 224(8):1410-1421. PubMed ID: 33598686
[TBL] [Abstract][Full Text] [Related]
40. Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
Wang H; Wen B; Chang X; Wu Q; Wen W; Zhou F; Guo Y; Ji Y; Gu Y; Lai Q; He Q; Li J; Chen J; Hou J
J Hepatol; 2021 Mar; 74(3):584-592. PubMed ID: 33039403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
